The Novel PI3K/mTOR Dual Inhibitor PQR309 in Pre-Clinical Lymphoma Models: Demonstration of Anti-Tumor Activity As Single Agent and in Combination and Identification of Gene Expression Signatures Associated with Response

被引：0

作者：

Tarantelli, Chiara ^{[1
]}

Gaudio, Eugenio ^{[1
]}

Kwee, Ivo ^{[1
,2
]}

Rinaldi, Andrea ^{[1
]}

Stifanelli, Matteo ^{[1
]}

Bernasconi, Elena ^{[1
]}

Barassi, Chiara ^{[1
]}

Hillmann, Petra ^{[3
]}

Stathis, Anastasios ^{[4
]}

Carrassa, Laura ^{[5
]}

Broggini, Massimo ^{[5
]}

Stussi, Georg ^{[4
]}

Fabbro, Doriano ^{[3
]}

Hebeisen, Paul ^{[3
]}

Betts, Frances ^{[3
]}

Wicki, Andreas ^{[6
]}

Zucca, Emanuele ^{[4
]}

Cmiljanovic, Vladimir ^{[3
]}

Bertoni, Francesco ^{[1
]}

机构：

[1] IOR Inst Oncol Res, Bellinzona, Switzerland

[2] Dalle Molle Inst Artificial Intelligence, Manno, Switzerland

[3] Piqur Therapeut AG, Basel, Switzerland

[4] IOSI Oncol Inst Southern Switzerland, Bellinzona, Switzerland

[5] IRCCS Ist Ric Farmacol Mario Negri, Milan, Italy

[6] Univ Basel Hosp, CH-4031 Basel, Switzerland

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 12 条

[1] PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
Tarantelli, Chiara
Gaudio, Eugenio
Arribas, Alberto J.
Kwee, Ivo
Hillmann, Petra
Rinaldi, Andrea
Cascione, Luciano
Spriano, Filippo
Bernasconi, Elena
Guidetti, Francesca
Carrassa, Laura
Pittau, Roberta Bordone
Beaufils, Florent
Ritschard, Reto
Rageot, Denise
Sele, Alexander
Dossena, Barbara
Rossi, Francesca Maria
Zucchetto, Antonella
Taborelli, Monica
Gattei, Valter
Rossi, Davide
Stathis, Anastasios
Stussi, Georg
Broggini, Massimo
Wymann, Matthias P.
Wicki, Andreas
Zucca, Emanuele
Cmiljanovic, Vladimir
Fabbro, Doriano
Bertoni, Francesco
CLINICAL CANCER RESEARCH, 2018, 24 (01) : 120 - 129
[2] Pre-clinical activity and mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas
Tarantelli, Chiara
Gaudio, Eugenio
Kwee, Ivo
Rinaldi, Andrea
Bernasconi, Elena
Cascione, Luciano
Hillmann, Petra
Stathis, Anastasios
Carrassa, Laura
Broggini, Massimo
Stussi, Georg
Fabbro, Doriano
Beaufils, Florent
Melone, Anna
Bohnacker, Thomas
Wymann, Matthias P.
Wicki, Andreas
Zucca, Emanuele
Cmiljanovic, Vladimir
Bertoni, Francesco
CANCER RESEARCH, 2015, 75
[3] Targeting the PI3K/mTOR Pathway in Lymphoma with PQR309 and PQR620: Single Agent Activity and Synergism with the BCL2 Inhibitor Venetoclax
Tarantelli, Chiara
Gaudio, Eugenio
Hillmann, Petra
Spriano, Filippo
Kwee, Ivo
Rinaldi, Andrea
Stathis, Anastasios
Zucca, Emanuele
Fabbro, Doriano
Cmiljanovic, Vladimir
Bertoni, Francesco
BLOOD, 2016, 128 (22)
[4] The dual PI3K/MTOR inhibitor PQR309 is active in mature B cell lymphoma cell lines bearing resistance to the PI3K-delta inhibitor idelalisib and specific gene expression features
Chiara, Tarantelli
Gaudio, Eugenio
Kwee, Ivo
Arribas, Alberto
Rinaldi, Andrea
Bernasconi, Elena
Cascione, Luciano
Hillmann, Petra
Stathis, Anastasios
Carrassa, Laura
Broggini, Massimo
Stussi, Georg
Fabbro, Doriano
Zucca, Emanuele
Cmiljanovic, Vladimir
Bertoni, Francesco
CANCER RESEARCH, 2016, 76
[5] Amdizalisib (HMPL-689), a highly selective PI3Kδ inhibitor, exhibits potent anti-tumor activity in pre-clinical B-cell lymphoma models
Hu, Jia
Wang, Jianhan
Dai, Xiaoming
He, Jianlin
Liang, Junqing
Yu, Ying
Yu, Juntao
Yang, Na
Wang, Linfang
Cai, Yu
Li, Xiong
Qing, Weiguo
Ren, Yongxin
Su, Weiguo
CANCER RESEARCH, 2022, 82 (12)
[6] GSK458 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in T Cell Lymphomas As a Single Agent and in Combination Therapy
Gu, Juan
Yang, Lianjuan
Gaughan, Dennis C.
He, Ling
Shen, Weina
Mavis, Cory
Hernandez-Ilizaliturri, Francisco J.
BLOOD, 2018, 132
[7] VS-5584, a dual PI3K/mTOR inhibitor, demonstrates robust activity in pre-clinical models of SCLC with the inhibition of both cancer stem cells and bulk tumor cells
Kolev, V.
Wang, Y.
Sprott, K.
Padval, M.
Pachter, J.
Weaver, D.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S53 - S53
[8] Combination Therapy of the Novel PI3K Inhibitor GDC-0941 and Dual PI3K/mTOR Inhibitor GDC-0980 with Trastuzumab-DM1 Antibody Drug Conjugate Enhances Anti-Tumor Activity in Preclinical Breast Cancer Models In Vitro and In Vivo
Sampath, D.
Fields, C.
Li, G.
Prior, W. W.
Parsons, K.
Friedman, L. S.
Lewis-Phillips, G. D.
CANCER RESEARCH, 2010, 70
[9] Combination of the Chk1 inhibitor (prexasertib) with a PI3K/mTOR inhibitor (LY3023414) induces synergistic anti-tumor activity in triple negative breast cancer (TNBC) models
Wu, Wenjuan
Donoho, Greg
Iversen, Philip
Dempsey, Jack
Capen, Andrew
Castanares, Mark
Stephens, Jennifer
Boehnke, Karsten
Reinhard, Christoph Reinhard
Lin, Aimee
CANCER RESEARCH, 2019, 79 (13)
[10] VS-5584 a dual mTORC1/2 and PI3K inhibitor has anti-tumor activity in multiple in vivo xenograft tumor models and enhanced efficacy in combination with cisplatin or docetaxel
Trombino, Anthony F.
Kolev, Vihren N.
Wright, Quentin G.
Xu, Qunli
Padval, Mahesh V.
CANCER RESEARCH, 2014, 74 (19)

← 1 2 →